tirzepatide deadline nears for discounted weight loss drugs: What to know GLP-1 Weight-Loss Drugs Off Shortage

FDA-approved pharmacotherapy alternatives include several options with established safety profiles: Semaglutide (Wegovy): A GLP-1 receptor agonist producing 12-15% weight loss, with cardiovascular benefits demonstrated in the SELECT trial and FDA-approved indication for reducing cardiovascular risk Liraglutide (Saxenda): A GLP-1 receptor agonist producing 5-8% weight loss [4] Phentermine-topiramate (Qsymia): FDA-approved combination producing 7-10% weight loss with established safety data Naltrexone-bupropion (Contrave): Combination targeting reward pathways and appetite, producing 5-9% weight loss [4] Orlistat (Xenical, Alli): Lipase inhibitor producing 3-5% weight loss with gastrointestinal side effects [4] Setmelanotide (Imcivree): For rare genetic obesity disorders (POMC, PCSK1, LEPR deficiency) [4] Metabolic and bariatric surgery should be considered for patients with BMI 40 kg/m or 35 kg/m with obesity-related comorbidities who have not achieved adequate weight loss with nonsurgical interventions

Strategies vary from launching new brands and products to just repositioning

Engage in regular follow-ups to track your progress and refine your plan for optimal results

Table 1 Summary of clinical studies investigating the combined effects of L-citrulline supplementation and exercise on muscle and vascular function in aging populations

the clinical benefit is unproven [1]

Among the 4 GLP-1RAs, Semaglutide was the most cost-effective obesity medication [38] [39]